FGFR3 and urinary bladder carcinoma: Erdafitinib (JNJ-42756493) (Table 2), a selective angiogenic TKI with high affinity to FGFR-1 (IC50 = 1.2 nM), FGFR-2 (IC50 = 2.5 nM), FGFR-3 (IC50 = 3.0 nM), and FGFR-4 (IC50 = 5.7 nM).461,462 As an FDA-accelerated drug, erdafitinib primarily aims to adult patients with locally advanced or metastatic urothelial cancer who carrying FGFR-2 or FGFR-3 gene mutations after platinum chemotherapy.463 Up to now, several phase II and phase III clinical trials in patients with bladder cancer are still ongoing (NCT03390504, NCT04172675, NCT02365597, NCT02465060, NCT03473743).